Novo Nordisk has informed the TGA that supply of Ozempic will continue to be limited until 31 December 2025, a spokesperson for Novo Nordisk told Australian Pharmacist
It probably will not replace tirzepatide for people pursuing maximum weight loss, given the roughly 2x efficacy gap
Genetic variants affecting GLP-1 and GIP receptor sensitivity do not predict exact medication response or guaranteed side effect avoidance, but they can support a more informed conversation about which GLP-1 option, dose strength, and escalation schedule might align with your biological profile
[22] Orent & Couch, supra note 5
Then massage it in place
Statinfibrate combination therapy is associated with an increased risk for abnormal transaminase levels, myositis, or rhabdomyolysis (26) and does not lower the risk of cardiovascular events more than simvastatin alone (27)